Glycemic control in patients with type 2 diabetes mellitus in Spain;Control glucémico en pacientes con diabetes mellitus tipo 2 en España

Revista Clinica Espanola

Volumn 214, Issue 8, 2014, Pages 429-436

  Perez A ^a,b   Mediavilla, J J ^c   Minambres I ^a   Gonzalez Segura D ^d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Medicina Familiar y Comunitaria Centro de Salud Burgos Rural   (Spain)

^d Departamento Médico Almirall SA ^*  (Spain)

Author keywords

Atherogenic dyslipidemia; Duration of diabetes; Glycemic control; Insulin therapy; Oral antidiabetic agents; Primary care; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C;

ABDOMINAL OBESITY; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE DURATION; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIMARY MEDICAL CARE; RISK FACTOR; SPAIN; TREATMENT OUTCOME; WEIGHT CHANGE; WEIGHT GAIN;

EID: 84927692720     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2014.05.028     Document Type: Article

References (38)

1. Soriguer F, Goday A, Bosch-Comas A, Bordiu E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia. 2012; 55:88-93.
2. Mata M, Antonanzas F Tafalla M, Sanz P. El coste de la diabetes tipo 2 en Espana. El estudio CODE-2. Gac Sanit. 2002; 16:511-20.
3. Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes. 2004; 53 Suppl 3:S39-47.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
5. Holman RR, Paul SK, Bethel M.A., Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-89.
6. Franch Nadal J., Artola Menendez S, Diez Espino J, Mata Cases M. Evolucion de los indicadores de calidad asistencial al diabetico tipo 2 en atención primaria (1996-2007). Programa de mejora continua de calidad de la Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud. Med Clin (Barc). 2010; 135:600-7.
7. Vinagre I, Mata-Cases M, Hermosilla E., Morros R, Fina F, Rosell M., et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care. 2012; 35:774-9.
8. Perez A, Franch J, Cases A., Gonzalez Juanatey JR, Conthe P, Gimeno E, et al Relación del grado de control glucémico con las características de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES Med Clin (Barc). 2012; 138:505-11.
9. Knaebel J, Irvin BR, Xie CZ Accuracy and clinical utility of a point-of-care HbA1c testing device. Postgrad Med. 2013; 125:91-8.
10. Inzucchi SE, Bergenstal RM, Buse J.B., Diamant M., Ferrannini E, Nauck M, et al Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364-79.
11. Menendez Torre E., Lafita Tejedor FJ, Artola Menendez S, Millan Nunez-Cortes J, Alonso Garcia A, Puig Domingo M, et al. Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Endocrinol Nutr. 2011; 58:112-20.
12. Ismail-Beigi F., Moghissi E, Tiktin M., Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011; 154:554-9.
13. Skyler JS, Bergenstal R, Bonow R.O., Buse J., Deedwania P, Gale EA, et al Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009; 32:187-92.
14. Orozco-Beltran D., Gil-Guillen VF, Quirce F., Navarro-Perez J, Pineda M, Gomez-de-la-Camara A, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract. 2007; 61:909-15.
15. Benito Lopez P., Garcia Mayor R, Puig Domingo M, Mesa Manteca J, Pallardo Sanchez LF, Faure Nogueras E, et al. Perfil de los pacientes con diabetes mellitus tipo 2, en la Atencion Primaria española. Rev Clin Esp. 2004; 204:18-24.
16. De Pablos Velasco P, Franch J, Banegas Banegas JR, Fernandez Anaya S, Sicras Mainar A, Diaz Cerezo S. Estudio epidemiológico del perfil clínico y control glucémico del paciente diabético atendido en centros de atención primaria en Espana (estudio EPIDIAP). Endocrinol Nutr. 2009; 56:233-40.
17. Laiteerapong N, John PM, Nathan A.G., Huang ES. Public health implications of recommendations to individualize glycemic targets in adults with diabetes. Diabetes Care. 2013; 36:84-9.
18. Huppertz E, Pieper L, Klotsche J., Stridde E, Pittrow D, Bohler S., et al. Diabetes Mellitus in German Primary Care: quality of glycaemic control and subpopulations not well controlled - results of the DETECT study. Exp Clin Endocrinol Diabetes. 2009; 117:6-14.
19. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008; 31:81-6.
20. Turner RC, Cull CA, Frighi V, Holman R.R., UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281:2005-12.
21. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with type 2 diabetes: a longitudinal study. BMC Public Health. 2005; 5:36.
22. Spann SJ, Nutting PA, Galliher J.M., Peterson KA, Pavlik VN, Dickinson LM, et al Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med. 2006; 4:23-31.
23. Blaha MJ, Gebretsadik T, Shintani A., Elasy TA. Waist circumference, not the metabolic syndrome, predicts glucose deterioration in type 2 diabetes. Obesity (Silver Spring). 2008; 16:869-74.
24. Thorn LM, Forsblom C, Fagerudd J., Thomas MC, Pettersson-Fernholm K, Saraheimo M, et al Metabolic syndrome in type 1 diabetes: Association with diabetic nephropathy and glycemic control (the Finn Diane study). Diabetes Care. 2005; 28:2019-24.
25. Saad M, Pettitt D, Mott D., Knowler W, Nelson R, Bennett P. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. The Lancet. 1989; 333:1356-9.
26. Ji LN, Lu JM, Guo X.H., Yang WY, Weng JP, Jia WP, et al Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013; 13:602.
27. Lopez-Simarro F Brotons C, Moral I, Cols-Sagarra C, Selva A, Aguado-Jodar A, et al. Inercia y cumplimiento terapéutico en pacientes con diabetes mellitus tipo 2 en atención primaria. Med Clin (Barc). 2012; 138:377-84.
28. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004; 27:1535-40.
29. Vinagre I, Sánchez-Hernández J, Sánchez-Quesada JL, María MÁ, de Leiva A, Pérez A. Switching to basal-bolus insulin therapy is effective and safe in long-term type 2 diabetes patients inadequately controlled with other insulin regimens. Endocrinol Nutr. 2013; 60:249-53.
30. Holman RR, Thorne KI, Farmer A.J., Davies MJ, Keenan JF, Paul S, et al Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007; 357:1716-30.
31. Holman RR, Farmer AJ, Davies M.J., Levy JC, Darbyshire JL, Keenan JF, et al Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009; 361:1736-47.
32. Cryer PE. Banting lecture hypoglycemia: the limiting factor in the management of IDDM. Diabetes. 1994; 43:1378-89.
33. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002; 45:937-48.
34. Standards of medical care in diabetes-2013. Diabetes Care. 2013; 36 Suppl 1:S11-66.
35. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010; 303:1410-8.
36. Liu SC, Tu YK, Chien M.N., Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network metaanalysis. Diabetes ObesMetab. 2012; 14:810-20.
37. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007; 50:1140-7.
38. Donnelly LA, Morris AD, Frier B.M., Ellis JD, Donnan PT, Durrant R, et al Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005; 22:749-55.